Hi @Gowtham_Rao, I am very interested in joining this working group. It seems this group is no longer active. Is this topic now under other working groups? Thank you!
No
This workgroup is unfortunately inactive
1 Like
Thank you for your reply!
Hi everyone,
Our team in Pfizer is still quite interested in this working group and we are hoping to see if we can help to re-activate the group. How should we do so?
If anyone was in this working group, do you mind to share what are the challenges you faced, and what’s the key reason that the group is now inactive? I already learned from Rao that the group led to the updated cost table (version 6), and also added features to Atlas for cost and utilization.
Thanks all!
Yi-Chien
Hi everyone,
Our team is also very interested in HEOR research using OMOP-CDM. We’ve conducted three studies on economic analyses and outcomes research using real-world data (RWD), which you can find here:
- [Economic burden of age-related macular degeneration] (JMIR Public Health and Surveillance - Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study)
- Economic burden and healthcare utilization of diabetic macular edema
- [Bayesian comparative effectiveness research with RCT and RWD] 2024 OHDSI global symposium showcase 77
While I’m not sure why the working group is currently inactive, I would love to participate and contribute to reactivating the HEOR working group. If anyone is interested, we could arrange a personal meeting at the OHDSI 2024 Global Symposium in New Jersey.
Looking forward to working together.
Thanks!
Kyungseon
Did you guys meet? And decide something?
Hi Christian,
Thank you for following up.
- Unfortunately, we haven’t had a chance to meet yet.
- No specific decisions have been made regarding reactivating the HEOR working group.
- I agree that it would be great to discuss this further in the forum and see if there are other interested members.
Looking forward to hearing if anyone else is open to joining the discussion.